Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Burden of Influenza and Respiratory Syncytial Virus Infection in Pregnant Women and Infants Under 6 Months in Mongolia: A Prospective Cohort Study

Burden of Influenza and Respiratory Syncytial Virus Infection in Pregnant Women and Infants Under 6 Months in Mongolia: A Prospective Cohort Study

  • Liling Chaw, 
  • Taro Kamigaki, 
  • Alexanderyn Burmaa, 
  • Chuluunbatiin Urtnasan, 
  • Ishiin Od, 
  • Gunregjaviin Nyamaa, 
  • Pagbajabyn Nymadawa, 
  • Hitoshi Oshitani



Pregnant women and infants under 6 months are at risk of influenza-related complications. Limited information exists on their community burden of respiratory viruses.

Methods and Findings

This prospective, observational open cohort study was conducted in Baganuur district, Ulaanbaatar, Mongolia during 2013/14 and 2014/15 influenza seasons. Influenza-like illness (ILI) and severe acute respiratory infection (sARI) were identified by follow-up calls twice a week. For those identified, influenza and respiratory syncytical virus (RSV) were tested by point-of-care test kits. We calculated overall and stratified (by trimester or age group) incidence rates (IR) and used Cox proportional hazard regression for risk factor analyses. Among 1260 unvaccinated pregnant women enrolled, overall IRs for ILI, sARI and influenza A were 11.8 (95% confidence interval (C.I):11.2–12.4), 0.1 (95%C.I:0.0–0.4), and 1.7 (95%C.I:1.5–1.9) per 1,000person-days, respectively. One sARI case was influenza A positive. IRs and adjusted hazard ratios (Adj.HR) for ILI and influenza A were lowest in the third trimester. Those with co-morbidity were 1.4 times more likely to develop ILI [Adj.HR:1.4 (95%C.I:1.1–1.9)]. Among 1304 infants enrolled, overall ILI and sARI IRs were 15.2 (95%C.I:14.5–15.8) and 20.5 (95%C.I:19.7–21.3) per 1,000person-days, respectively. From the tested ILI (77.6%) and sARI (30.6%) cases, the overall positivity rates were 6.3% (influenza A), 1.1% (influenza B) and 9.3% (RSV). Positivity rates of influenza A and RSV tend to increase with age. sARI cases were 1.4 times more likely to be male [Adj.HR:1.4 (95%C.I:1.1–1.8)]. Among all influenza A and RSV positive infants, 11.8% and 68.0% were respectively identified among sARI hospitalized cases.


We observed low overall influenza A burden in both groups, though underestimation was likely due to point-of-care tests used. For infants, RSV burden was more significant than influenza A. These findings would be useful for establishing control strategies for both viruses in Mongolia.


Pregnant women and infants under 6 months old are at risk of influenza-related complications, leading to hospitalizations [14]. This impact was observed among pregnant women during seasonal influenza season [5, 6] and more apparently during the pandemic (H1N1) 2009 [7]. Briefly, pregnant women in the third trimester were found to be 3–4 times more likely to be hospitalized for an acute cardiopulmonary illness during the inter-pandemic influenza season, when compared to post-partum women [6]. Also, pregnant women with influenza A(H1N1)pdm09 infection were about seven times more likely to be hospitalized and two times more likely to die, when compared to non-pregnant women of reproductive age [8].

Also, infants under 6 months are known to have higher hospitalization rates for both seasonal influenza and respiratory syncytical virus (RSV). In the United States, the influenza-related hospitalization rate was estimated to be 4.5 per 1,000 children under 6 months old [9], while that due to RSV was 16.9 per 1,000 children [10]. In a birth cohort in Kenya, infants under 6 months had the highest rate of RSV-associated disease [11].

Maternal influenza vaccination is one of the safe and cost-effective interventions of protecting both pregnant women as well as infants under 6 months, to whom direct influenza vaccination is not indicated [4, 12]. It was shown to reduce the frequency of febrile respiratory illnesses in pregnant women [13], as well as the frequency of influenza infection [13, 14] and hospitalization [15, 16] in infants under 6 months. Recognising its two-fold benefit, the WHO Strategic Advisory Group of Experts (SAGE) on immunization recommended that pregnant women should be vaccinated against influenza at any pregnancy stage [17]. Despite this, vaccination rate is still low in both developed [18] and developing [3] countries. Maternal RSV vaccination, when it is available, is also one useful strategy to protect infants under 6 months [19, 20]. RSV subunit vaccines are currently being developed for the adult population, including pregnant women [21].

There are a few reasons why Mongolia is chosen as the study site. First, maternal and child health is currently one of the important health issues in Mongolia due to its high birth rate and population growth. Between 2005 and 2014, the number of live births increased at an average rate of 6.4% [22, 23]. In 2014, the estimated annual birth rate is 20.9 per 1,000 persons [24]. Second, it was previously shown that children < 5 years old in Mongolia have the highest incidence of influenza-associated illness [25]. Third, the burden among pregnant women has never been assessed in the country, even though 24.1% of all influenza A(H1N1)pdm09-confirmed deaths in Mongolia were pregnant [26]. During the study period, the country’s national influenza vaccination policy did not include pregnant women as one of the recommended vaccine recipients [27].

Limited data exists on the disease burden of respiratory viruses for both populations at the community level. Therefore, we conducted a prospective observational cohort study on acute respiratory viruses for both groups during the 2013–14 and 2014–15 influenza seasons in a Mongolian community. The study objectives were to determine the incidence and risk factors of influenza-like illness (ILI), severe acute respiratory infection (sARI) and virus-positive cases (influenza A, influenza B and RSV) in pregnant women and infants under 6 months.

Material and Methods

Study site

Baganuur is a semi-urban district located at about 130 km away from the central part of Ulaanbaatar, Mongolia’s capital city. In 2013, it had an estimated population of 27,440. Medical services are provided mainly by one district hospital and four primary healthcare centers called Family General Practitioners (FGPs). We conducted the study in this district for two consecutive influenza seasons (October 1st 2013—April 30th 2014 and October 1st 2014—April 30th 2015).

Data collection

In Mongolia, all pregnant women and children < 2 years old are required to register and undergo medical check-ups at their FGPs, which are assigned based on their official residential address. All four FGPs in the district were used as the study entry point. All residents who registered at the FGPs and met the inclusion criteria (being pregnant or aged < 24 weeks during the study period) were enrolled. To include those who had already registered and those newly registered during the study period, enrolment was carried out continuously throughout the study period. Follow-up ends if any of the following occurred: a woman was no longer pregnant, a child reached 24 weeks of age, or any participant moved away from Baganuur district.

At the time of enrolment, a baseline questionnaire was administered to all participants to collect their demographic information. Prenatal information and household member demographics were also collected from pregnant women for both seasons. For infants under 6 months, information on birthweight, gestational age at delivery and presence of birth defects were collected for both seasons, while the household member demographics were collected only during the 2014/15 season. Household members who were < 18 years old were categorized as: young child (until 2 years), kindergarten-age (2–5 years), and school-age (6–17 years).

For pregnant women, initial antenatal examination is carried out by an obstetrician in the district hospital on their first check-up, and the results are recorded in the antenatal check-up record book. This book served as the major source of baseline data in this study. The obstetrician classifies all pregnant women as either normal or high risk to indicate whether she would undergo routine or extensive antenatal check-ups, respectively. The first day of the last menstruation was used to determine the start date of pregnancy and the trimester stages were defined as: first (0–13 weeks), second (14–26 weeks), and third (27 weeks and above). Baseline height and weight information were also collected to calculate the body mass index (BMI). We defined pregnant women as with co-morbidity if she has any of the following medical conditions that pre-disposes them to influenza-related complications [28]: pulmonary, cardiovascular, renal, and metabolic conditions.

For infants under 6 months, low birthweight was defined as those born weighing < 2500g. Three categories were defined for term of pregnancy [29, 30]: preterm, early term, and full term.

The primary outcome in this study was the occurrence of a case positive for either influenza A, influenza B or RSV. The secondary outcome was the occurrence of an ILI or a sARI case. An ILI case was defined as the sudden onset of fever of ≥ 38°C, or with history of fever, and cough within the last 7 days. A sARI case was defined as having ILI symptoms and requires hospitalization.

Throughout the study period, scheduled follow-up calls were carried out twice a week (one call every 2–5 days) to actively identify any ILI episodes among the study participants. When an ILI episode was identified, a timely home visit was made to interview him/her with a case report form and to collect a nasopharyngeal swab for on-site testing with a point-of-care test kit (QuickNavi–Flu + RSV, Denka Seiken Co. Ltd). This commercially available kit enables simultaneous detection of influenza A, influenza B and RSV. In the subsequent two follow-up calls, the resolution of ILI symptoms was also recorded. If the ILI case had recovered from symptoms on the day of follow-up call, that date was used as the date of symptom resolution.

At the district hospital, information on sARI episodes (admission and discharge dates, symptoms presented, clinical indicators, diagnosis at discharge and outcome, point-of-care test results) were collected. There were some cases who initially visited the FGP for testing, then later referred for hospitalization. An episode whose interval between FGP visit and hospital admission is < 7 days was considered as the same illness episode.

The district hospital and all four FGPs in Baganuur are also a part of the national ILI surveillance program in Mongolia. Nasopharyngeal swabs were collected randomly from ILI cases and routinely tested for influenza virus using real-time polymerase chain reaction (PCR). Some randomly selected samples were further tested for other respiratory viruses, including RSV. According to this surveillance [31], three influenza strains [A(H1N1)pdm09, A(H3N2), and B] were detected during the 2013/14 season, while A(H3N2) and RSV were detected during the 2014/15 season (S1 Fig). Some of our study participants (5.6%) were tested under this surveillance, particularly during periods of limited test kit availability. These results were also collected and combined into the analyses.

All field staff involved had been trained with participant interviewing as well as sample collecting, testing and result interpretation. The field supervisor monitored all activity from data collection to encoding.

Ethical Approval

Ethical approval for this study was obtained from the Ethics Committee of Tohoku University, Graduate School of Medicine, Sendai, Japan (2013-1-253), the Scientific Committee of National Center of Communicable Diseases, Mongolia (14/126), and the Ministry of Health, Mongolia (2014–02). Written informed consent was obtained from eligible participants or their parents/guardians before study enrolment as well as from identified ILI and sARI cases before data and sample collection.

Statistical analysis

Overall incidence rates (IR) were derived by dividing the actual number of cases detected with the total person-days at risk, and 95% confidence intervals (C.I) were calculated using exact methods. Total person-days were calculated based on the study entry and leaving dates. For participants with ILI or sARI, the symptomatic period was considered as days not-at-risk of infection and therefore not included in the denominator. For those with missing symptom resolution dates, we set 7 days as the duration of symptoms, based on previous studies on adults [32] and children < 1 year old [33]. For sARI cases, we defined the symptomatic period as the number of days hospitalized.

We also investigated the risk factors of getting ILI, sARI and virus positive cases. Participants who did not have ILI symptoms (non-ILI group) were initially compared univariately with the ILI cases and also with each virus positive cases (S3 and S4 Tables). sARI cases were only investigated for infants under 6 months, and they were compared univariately with those who were not hospitalized with sARI (non-sARI group) (S4 Table). Parametric (Student’s t and chi-square) and non-parametric (Wilcoxon rank sum and Fisher’s exact) tests were used whenever appropriate. Factors with a p-value of ≤ 0.1 and deemed relevant for acquiring illness episodes were then included in the Cox proportional hazards (PH) regression model. In all models runs, non-ILI or non-sARI were used as the comparison group. Participants with multiple episodes within each season were also accounted for, in both un-adjusted and adjusted models. To ensure that the model assumptions were met, diagnostic tests on the proportional hazards assumption were done and the residuals were also checked. For pregnant women, all co-variates except age at enrolment were categorically included in the final Cox PH model. Alternative model runs using categorized age quartiles were consistent with the main results reported. For infants under 6 months, all co-variates included were categorical. A p-value of < 0.05 was considered statistically significant.

We hypothesize that trimester stage (for pregnant women) and age group (for infants under 6 months) could contribute to differences in infection risk. Therefore, we also stratified the IR calculations accordingly and included them as the time-dependent variable in the Cox PH model. Microsoft Excel and R software, version 3.2.0 [34] were used for all analyses.


Distribution of ILI and sARI cases, and circulating viruses in both populations

Fig 1 shows the weekly number of ILI and sARI cases in pregnant women and infants under 6 months during the study period. Most ILI and sARI cases tend to occur between November to March, coinciding with winter months in Mongolia. The temporal trend of sARI correlated with that of ILI in infants (r2 = 0.71) while there were only 2 sARI cases observed in pregnant women.

Fig 1. The weekly number of influenza-like illness (ILI) [orange] and severe acute respiratory infections (sARI) [purple] cases during the 2013/14 (left) and 2014/15 (right) seasons, for pregnant women (a) and infants under 6 months (b).

The black lines indicate periods of limited point-of-care test kit supply, thus testing was compromised in those weeks.

Fig 2 shows the weekly number of virus positives detected in the two populations. In general, positive cases were detected mainly from January to February, coinciding with the high activities of both ILI and sARI. All three targeted viruses were detected during the 2013/14 season, while influenza B virus was not detected during the 2014/15 season. This was quite consistent with data from the national ILI surveillance, except that RSV was not detected during the 2013/14 season (S1 Fig). There were periods of limited point-of-care test kit availability at the beginning of both seasons and early December in the 2014/15 season. Hence, virus testing was compromised during those periods.

Fig 2. The weekly number of virus positives detected from ILI and sARI cases during the 2013/14 (left) and 2014/15 (right) seasons, for pregnant women (a) and infants under 6 months (b).

The bars show the number of positive cases for influenza A (red), influenza B (blue) and RSV (green). The black lines indicate periods of limited point-of-care test kit supply, thus testing was compromised in those weeks. The overall testing rate for ILI and sARI cases are 94.8% and 100%, respectively, for pregnant women and 77.6% and 30.6%, respectively, for infants under 6 months.

Incidence rates of ILI, sARI and virus positives for pregnant women

We individually enrolled 1,260 pregnant women and they were followed for a total of 120,887 person-days. The population characteristics were quite different for the two seasons (S1 Table). Briefly, the 2014/15 season cohort tend to be more educated, employed, overweight, enrolled at an earlier gestational age, and did not have co-morbidity; though these differences may possibly be due to chance. The median age at enrolment was 27 years (range: 16–44) and 43.0% were enrolled during the first trimester. Seven pregnant women refused to join the study. None had received the influenza vaccine.

A total of 174 ILI episodes (13.8%) were detected from 160 pregnant women. There were 12 and 2 women with 2 and 3 ILI episodes respectively, during the same influenza season. Among the ILI cases with recorded symptom resolution dates (85.6%), the mean interval to resolution was 8.1 days (range: 3–20). The overall IR for ILI was 11.8 per 1,000 person-days (95% C.I: 11.2–12.4) (Table 1).

Table 1. Incidence rates (IRs) of ILI and sARI cases detected for pregnant women, stratified by trimester stage and for the overall cohort.

Among all tested ILI cases (n = 165), 26 (15.8%) tested positive for influenza A, 2 (1.2%) for influenza B, and 4 (2.4%) for RSV. This gives an overall IR of 1.7 per 1,000 person-days (95% C.I: 1.5–1.9) for influenza A, 0.1 per 1,000 person-days (95% C.I: 0.1–0.2) for influenza B, and 0.3 per 1,000 person-days (95% C.I: 0.2–0.4) for RSV (Table 2). The majority of samples (96.0%) were tested within 5 days after symptom onset. During the 2014/15 season, 2 women tested positive for both influenza A and RSV from separate ILI episodes.

Table 2. Incidence rates (IRs) of influenza A, influenza B and RSV detected for pregnant women, stratified by trimester stage and for the overall cohort.

Two sARI cases were also detected, giving an overall sARI incidence rate of 0.1 per 1,000 person-days (95% C.I: 0.04–0.4). One case tested negative in the 2014/15 season during her second trimester, and another was positive for influenza A during the 2013/14 season during her first trimester. No virus co-detection and deaths were observed during the study period.

IRs for ILI and influenza A were the lowest in the third trimester (Tables 1 and 2). Sensitivity analysis using total person-days only in January and February also revealed the same trend as the main result. This analysis was done because all influenza A positive cases were detected only in the latter months. Similar trend was also observed in the risk factor analysis for both ILI (Table 3) and influenza A (Table 4). When compared to the first trimester, pregnant women in the third trimester were 78% less likely to have influenza A detected, after adjusting for age and presence of prior pregnancy [Adjusted hazard ratio (Adj. HR): 0.22 (95% C.I: 0.07–0.73)]. Pregnant women were also 50% [Adj. HR: 0.50 (95% C.I: 0.34–0.75)] and 63% [Adj. HR: 0.37 (95% C.I: 0.25–0.55)] less likely to develop an ILI episode in the second and third trimesters, respectively, when compared to the first trimester. In addition, pregnant women who have any co-morbidity were 43% more likely to develop an ILI episode [Adj. HR: 1.43 (95% C.I: 1.06–1.94)].

Table 3. Risk factor analysis results when comparing ILI cases and non-ILI among pregnant women.

Co-variates were chosen based on initial univariate analyses (S3 Table). Estimates in bold indicate statistically significant co-variates.

Table 4. Risk factor analysis results when comparing influenza A positive cases and non-ILI among pregnant women.

Co-variates were chosen based on initial univariate analyses. Estimates in bold indicate statistically significant co-variates.

ILI and sARI incidence, and virus positivity rates for infants under 6 months

We individually enrolled 1,304 infants under 6 months and they were followed for a total of 122,344 person-days. They were mainly healthy, whereby 88.4% were born full term, 2.9% had low birthweight, and 3.5% were born with a certain birth defect. Their baseline characteristics were similar for both seasons, except that there were significantly more full term infants in the 2014/15 season (S2 Table). The median age at enrolment was 12 days (range: 0–167). During the 2013/14 season, 99.9% were breastfed for 6 months.

A total of 246 ILI episodes (18.9%) were detected from 201 infants under 6 months. There were 37, 7 and 1 infants with 2, 3, and 4 ILI episodes, respectively, during the same influenza season. Among the ILI cases with recorded symptom resolution dates (82.2%), the mean interval to resolution was 7.5 days (range: 1–14). The overall ILI IR was 15.2 per 1,000 person-days (95% C.I: 14.5–15.8) (Table 5). From all tested ILI cases (n = 191), we detected 15 (7.9%) influenza A, 3 (1.6%) influenza B and 8 (4.2%) RSV cases. Most samples were tested within 5 days after symptom onset (98.8%). During the 2013/14 season, we detected RSV twice (on separate occasions) from one female infant of low birthweight and did not result in sARI hospitalization.

Table 5. Incidence rates (IRs) of ILI and sARI cases for infant under 6 months, stratified by age groups and for the overall cohort.

A total of 255 sARI hospitalized cases (19.6%) were detected from 218 infants under 6 months, giving an overall sARI IR of 20.5 per 1,000 person-days (95% C.I: 19.7–21.3) (Table 5). There were 30 and 8 infants who were hospitalized for sARI twice and thrice, respectively, during the same influenza season. Also, 36 (14.1%) of them had prior visit to the FGP for the same illness episode. The mean length of hospital stay was 8.9 days (range: 0–33). For all sARI cases, 74.3% were admitted within 5 days after symptom onset. A total of 23 (18.3%) and 55 (42.6%) cases were tested during the 2013/14 and 2014/15 season, respectively. This gives an overall sARI testing rate of 30.6%. During the 2013/14 season, 4 (17.4%) tested positive for RSV and 2 (8.7%) for influenza A while 13 (23.6%) RSV and no influenza A cases were detected during the 2014/15 season. No influenza B positive sARI cases were detected from either season. No virus co-detection and deaths were also observed during the study period.

Overall, we detected a total of 17 (6.3%) influenza A, 3 (1.1%) influenza B, and 25 (9.3%) RSV cases among the tested ILI and sARI samples (n = 269) (Table 6). Among the total positive cases, 2 (11.8%) influenza A and 17 (68.0%) RSV cases were detected among hospitalized cases with sARI. After stratification by age group, 16–24 weeks old infants had the highest IR for ILI [26.8 per 1,000 person-days (95% C.I: 25.2–28.5)] and sARI [25.8 per 1,000 person-days (95% C.I: 24.2–27.4)] (Table 5). The same trend was also observed in the positivity rates of influenza A and RSV (Table 6). The increase in the RSV positivity rate started from the 8–15.9 weeks old group. Also, sARI cases were 1.4 times more likely to be male, when compared to non-sARI [Adj. HR: 1.40 (95% C.I: 1.07–1.83)] (Table 7).

Table 6. Total positive case numbers of influenza A, influenza B and RSV and also those hospitalized for sARI, stratified by age groups and for the overall cohort.

Table 7. Risk factor analysis results when comparing sARI cases and non-sARI among infants under 6 months.

Co-variates were chosen based on initial univariate analyses (S4 Table). Estimates in bold indicate statistically significant co-variates.


We prospectively followed a cohort of unvaccinated pregnant women and infants under 6 months to actively detect acute respiratory illnesses for two consecutive influenza seasons. Among pregnant women, we observed low overall IR for influenza A. Both ILI and influenza A IR were the lowest in the third trimester. There were also few sARI and influenza A positive hospitalized cases. Also, pregnant women with co-morbidity have about 1.4 times higher risk of developing an ILI episode. Among infants under 6 months, we observed moderately high ILI and sARI IRs. Older infants (16–24 weeks old) had higher ILI IR and positivity rates (of influenza A and RSV), while younger male infants (0–7.9 weeks old) had higher sARI IR. Among all influenza A and RSV positive infant cases, 11.8% and 68.0% were respectively identified among hospitalized cases with sARI.

One study in the United States [35] reported both ILI and sARI IR for pregnant women in all three trimesters and they observed high IRs, especially for sARI. Both ILI and sARI IRs in the study are also higher than that previously reported for the reproductive-age population (15–49 years) in Baganuur [36] and Mongolia [25], though it could possibly be due to active case search in the study. Expanding this study to include non-pregnant women of reproductive-age would allow us to see any impact of pregnancy in acquiring ILI and sARI. These Mongolian studies also reported incidence rates for young children, though aggregates of 0–11 months was used. Here, ILI IR in this study is higher than that reported in Baganuur [36]. Relatively high infant ILI IRs were also previously reported from Bangladesh [13] and the United States [14]. Nevertheless, caution should be taken for interpreting these direct comparisons due to differences in case detection methods, study season, and health-seeking tendencies, that is between women with and without pregnancy, as well as between younger and older infants.

The same study from Mongolia [25] also reported influenza positive rates by age group. The overall influenza positive rates for both ILI and sARI cases were lowest in the 0–11 month age group and highest in the reproductive age groups (16–44 years). Our study findings for infants under 6 months were consistent with the former, as more RSV positives than influenza were detected. The latter was also consistent with this study as pregnant women were mainly positive for influenza A. RSV infection was also documented for young working adults [37], though the attack rate was lower and symptom severity was milder than those of infants. Despite the fact that influenza B can affect people of all ages, only few influenza B cases were detected in both pregnant women and infants, presumably reflecting the circulation of influenza virus in the community.

Both IR and adjusted HR of influenza A were lowest for pregnant women in the third trimester, which could be due to differences in virus exposure at each trimester stage. Studies in the United States have shown that women in the third trimester tend to engage in lesser leisure activities [38] and spend more time at home [39]. Although it is uncertain whether both tendencies are also observed among Mongolians, it can lead to less interaction with others in the community, thus decreasing the probability of acquiring respiratory infections. Notably, we also observed the same finding in the risk factor analysis for ILI, after accounting for the presence of co-morbidity as well as possible transmission in the household (presence of kindergarten-age child) and workplace (employment status). This suggests that settings other than household and workplace may contribute to a certain risk of acquiring ILI and possibly influenza A infections. However, our finding contradicts with that in a previous study which showed high IR of influenza A in the third trimester [40]. Experimental studies have reported that the immune system switch to defensive mode during pregnancy [41]. Defensive immune responses (via phagocytic cells and α-defensins 1–3) are elevated throughout the pregnancy period [41]. Estrogen and progesterone levels, which surge from the first trimester [42], further strengthens this by stimulating anti-inflammatory responses [43]. This means that the immune system is capable of preventing the establishment of viral infections as pregnancy progresses, and that there is little immunological basis for increasing susceptibility to influenza infection [44]. Hence, our study finding is in fact more consistent to what is known with the immunological changes during pregnancy.

We also observed low sARI IR among pregnant women and only one was positive for influenza A. This observation is in line with some studies [45, 46], but there are also many reports of increased influenza-associated hospitalization rates during the inter-pandemic periods [5, 6, 35, 4749]. Our study findings could firstly be due to the relatively mild influenza seasons. Antigenic changes to the circulating strains seemed limited during both seasons under study, as the WHO-recommended vaccine strains were the same [50]. Thus, the enrolled pregnant women may have already had the infection to a similar strain prior to current pregnancy. Secondly, it could also be the low sample size of this study, which makes it difficult to detect severe illnesses that occur at a low rate.

We also found that pregnant women with co-morbidity had 1.4 times higher risk of developing an ILI episode, a finding which is consistent with previous studies [35]. Although this HR estimate was for both seasons, additional analysis for each season revealed significance only for the 2014/15 season. When compared to the 2013/14 season, the 2014/15 season had a lower proportion of pregnant women with co-morbidity enrolled and influenza A activity was also higher. This thus suggests that having co-morbidity is in fact a risk factor of developing ILI symptoms associated with influenza among pregnant women.

The ILI and sARI IR for infants under 6 months were the highest among the 16–24 weeks old group and similar trend was also observed in the positivity rates of both influenza A and RSV. In fact, 100% and 82.4% of the influenza A and RSV positive sARI cases, respectively, were found in those aged 8 weeks or older. Notably, this finding for RSV is consistent with that in Kenya [51]. This could be explained by the waning of passively-acquired maternal antibodies. Infants under 6 months who had acquired maternal antibodies against influenza [52, 53] and RSV [54] were reported to be protected from severe illness and had delayed symptom onset. Also, protection from maternal antibodies tends to wane after the first 2–3 months of life. Previous studies reported the half-life of passively-acquired maternal antibodies to be 21–53 days against influenza [52, 53, 55, 56] and 26–78 days against RSV [5759].

sARI IR was also high among the 0–7.9 weeks old infants, giving the impression of low IR among the 8–15.9 weeks old. However, this could be falsely elevated due to two reasons. First, young infants tend to exhibit signs of breathing difficulties, regardless of infection severity. Thus, parents/guardians tend to bring them directly to the hospital for immediate care. In fact, only 38 sARI cases (14.8%) were referred to the hospital from the FGP; hence suggesting a small number of ‘true’ sARI cases. Second, Mongolia follows the integrated management of childhood illness (IMCI) guidelines, whereby infants < 2 months old with fever are to be directly admitted to the hospital as a sARI case [60]. Hence, the high tendency to seek healthcare at the hospital and the implementation of the IMCI guidelines could explain the high sARI IR among younger infants. This could also be one reason why the overall IR for sARI was higher than that of ILI.

We also observed that 68.0% of RSV-positives detected were hospitalized with sARI, which is highly disproportionate when compared to that of influenza A (11.8%). This tendency is consistent with previous studies on hospitalized infants in the United States [9, 10, 61] and Thailand [62]. This data indicates that RSV caused more severe illness that required hospitalization among infants under 6 months in Baganuur. As the testing rate was low, particularly for sARI cases, it means that the actual proportion of hospitalized cases for both viruses could be much higher.

Infant sARI cases were 1.4 times more likely to be males, a trend that is consistent with previous reports [63] and also seen with RSV-associated hospitalizations [64]. When compared to females, young male infants tend to have reduced airway function [65, 66] and also tend to be more susceptible to infection [67]. In addition, all the RSV positive sARI cases were born full term. This means that RSV disease can also affect healthy infants, a finding in line with previous studies [10, 68].

Some study limitations need to be addressed. First, point-of-care test was the main diagnostic method used, which could lower the sensitivity of virus detection. A meta-analysis on influenza test kit evaluation studies reported a pooled sensitivity and specificity of 62.3% and 98.2%, respectively [69]. Thus, the incidence and positivity rates reported in this study are an underestimate, possibly by about 40%. For RSV, antigen detection methods are known to be considerably less sensitive particularly for adults [70]. We used point-of-care test kits mainly due to the limited laboratory capacity to test samples with real-time PCR. It also allowed us to simultaneously test for RSV, as the local laboratory only tests routinely for influenza. In order to ensure higher viral loads in the samples taken, efforts were made to identify cases within 5 days of symptom onset, and to test them as soon as possible upon identification. Second, there was a limited supply of point-of-care test kits in some periods of the study, resulting in a low overall testing rate for the sARI cases among infants (30.6%). This remains to be a major limitation even though we have improved the sARI testing rate from 18.1% in the 2013/14 season to 42.6% in the 2014/15 season. Hence, the positive rates reported for the infants under 6 months are an underestimate. Third, as a consequence of using point-of-care test kits, we also could not provide the IR by influenza subtype and RSV genotype. Fourth, we did not assess the use of non-pharmaceutical interventions, such as hand washing and facemask usage, in our study population. This could possibly affect the risk factor analysis results. Fifth, we did not detect enough virus-positive cases for both seasons to assess their risk factors. This could merely reflect the low influenza and RSV activities in this community and thus caution must be taken to extrapolate our findings to other areas in Mongolia. Sixth, we used the dates of follow-up and hospitalization to determine the symptomatic period for ILI and sARI IR calculations, respectively. These dates do not strictly reflect on each clinical course and may affect the calculated IRs. Lastly, we collected household demographic information among infants only for the 2014/15 season. As a result, these data were excluded from the risk factor analyses for both seasons.

In conclusion, we reported the results of a prospective, observational open cohort study conducted in a community setting for two targeted high-risk groups, during two consecutive influenza seasons in Mongolia. We observed a low overall influenza A burden for pregnant women in terms of incidence and hospitalization rates, though underestimation was likely due to point-of-care tests used. One surprising finding is the low influenza A incidence rate among the third trimester women, despite their particularly high risk of developing influenza-related severe illness. While for infants under 6 months, the incidence of ILI and sARI was moderately high. An important note here is the high number of RSV positives who got hospitalized when compared to that of influenza A, despite the low testing rate. Including additional data from subsequent influenza seasons would help to ascertain these findings. Despite its limitations, our study findings add into the currently limited knowledge on the burden of seasonal influenza for both groups. This is also the first study of its kind in Mongolia, a developing country where maternal and child health is an important health topic.

Supporting Information

S1 Dataset. Dataset for pregnant women, for incidence rate calculation and risk factor analysis.


S2 Dataset. Dataset for infants under 6 months, for incidence rate calculation and risk factor analysis.


S1 Fig. The weekly number of positive cases detected in Baganuur district for 2013/14 (left) and 2014/15 (right) seasons, based on the national ILI surveillance [31].

The bars show the number of positive cases for influenza A(H3N2) [brown], influenza A(H1N1)pdm09 [pink], influenza B [blue] and RSV [green].


S1 Table. Baseline characteristics of the pregnant women cohort and its comparison between two seasons.


S2 Table. Baseline characteristics of the infants under 6 months cohort and its comparison for the each season.


S3 Table. Characteristics of the ILI cases and non-ILI for the pregnant women cohort.


S4 Table. Characteristics of the (a) ILI cases and non-ILI, and (b) sARI cases and non-sARI for the infants under 6 months cohort.



The authors would like to express their gratitude to the following for their valuable support in this study: All personnel involved in the primary healthcare clinics and district hospital in Baganuur; personnel in National Influenza Center (NIC) and National Center for Communicable Diseases (NCCD) in Ulanbataar, Mongolia; Denka Seiken Co. Ltd, Japan who kindly donated point-of-care test kits in the 2014/15 season; and Dr. Mayuko Saito for her useful advice on the risk factor analyses. LC would also like to thank the MEXT Monbukagakusho scholarship program for financial support during her graduate study in Japan.

Author Contributions

Conceived and designed the experiments: LC TK PN HO. Analyzed the data: LC TK HO AB. Wrote the paper: LC TK HO. Enroll and follow up patients: CU IO GN AB.


  1. 1. Blanchard-Rohner G, Siegrist CA. Vaccination during pregnancy to protect infants against influenza: Why and why not? Vaccine. 2011;29(43):7542–50. pmid:21820480
  2. 2. Goodnight WH, Soper DE. Pneumonia in pregnancy. Crit Care Med. 2005;33(10 (Suppl.)): S390–S7.
  3. 3. Ortiz JR, Englund JA, Neuzil KM. Influenza vaccine for pregnant women in resource-constrained countries: A review of the evidence to inform policy decisions. Vaccine. 2011;29(27):4439–52. pmid:21550377
  4. 4. Rasmussen SA, Jamieson DJ, Uyeki TM. Effects of influenza on pregnant women and infants. Am J Obstet Gynecol. 2012;207(3, Supplement):S3–S8.
  5. 5. Cox S, Posner S, McPheeters M, Jamieson D, Kourtis A, Meikle S. Hospitalizations with respiratory illness among pregnant women during influenza season. Obstet Gynecol. 2006;107(6):1315–22. pmid:16738158
  6. 6. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of Influenza on Acute Cardiopulmonary Hospitalizations in Pregnant Women. Am J Epidemiol. 1998;148(11):1094–102. pmid:9850132
  7. 7. Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, Biggerstaff MS, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. The Lancet. 2009;374(9688):451–8.
  8. 8. Van Kerkhove MD, Vandemaele KAH, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, et al. Risk Factors for Severe Outcomes following 2009 Influenza A (H1N1) Infection: A Global Pooled Analysis. PLoS Med. 2011;8(7):e1001053. pmid:21750667
  9. 9. Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, et al. The Underrecognized Burden of Influenza in Young Children. N Engl J Med. 2006;355(1):31–40. pmid:16822994
  10. 10. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The Burden of Respiratory Syncytial Virus Infection in Young Children. N Engl J Med. 2009;360(6):588–98. pmid:19196675
  11. 11. Nokes DJ, Okiro EA, Ngama M, Ochola R, White LJ, Scott PD, et al. Respiratory Syncytial Virus Infection and Disease in Infants and Young Children Observed from Birth in Kilifi District, Kenya. Clin Infect Dis. 2008;46(1):50–7. pmid:18171213
  12. 12. Steinhoff MC, MacDonald N, Pfeifer D, Muglia LJ. Influenza vaccine in pregnancy: policy and research strategies. The Lancet. 2014;383(9929):1611–3.
  13. 13. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of Maternal Influenza Immunization in Mothers and Infants. N Engl J Med. 2008;359(15):1555–64. pmid:18799552
  14. 14. Eick AA, Uyeki TM, Klimov A, Hall H, Reid R, Santosham M, et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatr Adolesc Med. 2011;165(2):104–11. pmid:20921345
  15. 15. Poehling KA, Szilagyi PG, Staat MA, Snively BM, Payne DC, Bridges CB, et al. Impact of maternal immunization on influenza hospitalizations in infants. Am J Obstet Gynecol. 2011;204(6, Supplement):S141–S8.
  16. 16. Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Vázquez M. Influenza Vaccine Given to Pregnant Women Reduces Hospitalization Due to Influenza in Their Infants. Clin Infect Dis. 2010;51(12):1355–61. pmid:21058908
  17. 17. WHO position paper on influenza vaccines—November 2012. Wkly Epidemiol Rec. 2012;87:461–76.
  18. 18. Lu P, Bridges CB, Euler GL, Singleton JA. Influenza vaccination of recommended adult populations, U.S., 1989–2005. Vaccine. 2008;26(14):1786–93. pmid:18336965
  19. 19. Chu HY, Englund JA. Maternal Immunization. Clin Infect Dis. 2014;59(4):560–8. pmid:24799324
  20. 20. Meng J, Stobart CC, Hotard AL, Moore ML. An Overview of Respiratory Syncytial Virus. PLoS Pathog. 2014;10(4):e1004016. pmid:24763387
  21. 21. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine. 2013;31, Supplement 2 (Decade of Vaccines):B209–B15.
  22. 22. Social and economic situation of Mongolia (As of the preliminary result of 2013) National Statistical Office of Mongolia; 2014 [Accessed 20 May 2014]. Available:
  23. 23. Social and economic situation of Mongolia (As of the preliminary result of 2014) National Statistical Office of Mongolia; 2015 [Accessed 15 May 2015]. Available:
  24. 24. Central Intelligence Agency (CIA). The World Factbook: Mongolia [Accessed 18 Nov 2014]. Available:
  25. 25. Burmaa A, Kamigaki T, Darmaa B, Nymadawa P, Oshitani H. Epidemiology and impact of influenza in Mongolia, 2007–2012. Influenza Other Respi Viruses. 2014;8(5):530–7.
  26. 26. Baigalmaa J, Tuul T, Darmaa B, Soyolmaaa E. Analysis of fatal outcomes from influenza A(H1N1)pdm09 in Mongolia. Western Pac Surveill Response J. 2012;3(3):43–8. pmid:23908923
  27. 27. Dwyer D, Barr I, Hurt A, Kelso A, Reading P, Sullivan S, et al. Seasonal influenza vaccine policies, recommendations and use in the World Health Organization's Western Pacific Region. Western Pac Surveill Response J. 2013;4(3):51–9. pmid:24319615
  28. 28. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB, Advisory Committee on Immunization Practices (ACIP), et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-8):1–40. pmid:16086456
  29. 29. Spong CY. Defining “term” pregnancy: Recommendations from the defining “term” pregnancy workgroup. JAMA. 2013;309(23):2445–6. pmid:23645117
  30. 30. American College of Obstetricians and Gynecologists. Definition of term pregnancy. Committee Opinion No. 579.: Obstet Gynecol; 2013. p. 1139–40. pmid:24150030
  31. 31. Ministry of Health Mongolia, National Centre of Communicable Diseases, National Influenza Centre 2014 [Accessed 9 May 2014]. Available:
  32. 32. Macfarlane JT, Macfarlane RM, Rose DH, Colville A, Guion A. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. The Lancet. 1993;341(8844):511–4.
  33. 33. Jedrychowski W, Galas A, Pac A, Flak E, Camman D, Rauh V, et al. Prenatal Ambient Air Exposure to Polycyclic Aromatic Hydrocarbons and the Occurrence of Respiratory Symptoms over the First Year of Life. Eur J Epidemiol. 2005;20(9):775–82. pmid:16170661
  34. 34. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2014. Available:
  35. 35. Dodds L, McNeil SA, Fell DB, Allen VM, Coombs A, Scott J, et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. Can Med Assoc J. 2007;176(4):463–8.
  36. 36. Nukiwa N, Burmaa A, Kamigaki T, Darmaa B, Od J, Od I, et al. Evaluating influenza disease burden during the 2008–2009 and 2009–2010 influenza seasons in Mongolia. Western Pac Surveill Response J. 2011;1(1):16–22.
  37. 37. Hall CB, Long CE, Schnabel KC. Respiratory Syncytial Virus Infections in Previously Healthy Working Adults. Clin Infect Dis. 2001;33(6):792–6. pmid:11512084
  38. 38. Evenson KR, Wen F. National trends in self-reported physical activity and sedentary behaviors among pregnant women: NHANES 1999–2006. Prev Med. 2010;50(3):123–8. pmid:20053370
  39. 39. Nethery E, Brauer M, Janssen P. Time-activity patterns of pregnant women and changes during the course of pregnancy. J Expo Sci Environ Epidemiol. 2008;19(3):317–24. pmid:18478047
  40. 40. Lindsay L, Jackson LA, Savitz DA, Weber DJ, Koch GG, Kong L, et al. Community Influenza Activity and Risk of Acute Influenza-like Illness Episodes among Healthy Unvaccinated Pregnant and Postpartum Women. Am J Epidemiol. 2006;163(9):838–48. pmid:16554352
  41. 41. Kraus T, Engel S, Sperling R, Kellerman L, Lo Y, Wallenstein S, et al. Characterizing the Pregnancy Immune Phenotype: Results of the Viral Immunity and Pregnancy (VIP) Study. J Clin Immunol. 2012;32(2):300–11. pmid:22198680
  42. 42. Pazos M, Sperling R, Moran T, Kraus T. The influence of pregnancy on systemic immunity. Immunol Res. 2012;54(1–3):254–61. pmid:22447351
  43. 43. Robinson DP, Klein SL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm Behav. 2012;62(3):263–71. pmid:22406114
  44. 44. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and Infection. N Engl J Med. 2014;370(23):2211–8. pmid:24897084
  45. 45. Mullooly JP, Barker WH, Nolan TF. Risk of acute respiratory-disease among pregnant-women during influenza-A epidemics. Public Health Rep. 1986;101(2):205–11. pmid:3083477
  46. 46. Black SB, Shinefield HR, France EK, Fireman BH, Platt ST, Shay D, et al. Effectiveness of Influenza Vaccine during Pregnancy in Preventing Hospitalizations and Outpatient Visits for Respiratory Illness in Pregnant Women and Their Infants. Amer J Perinatol. 2004;21(06):333–9.
  47. 47. Schanzer DL, Langley JM, Tam TW. Influenza-Attributed Hospitalization Rates Among Pregnant Women in Canada 1994–2000. J Obstet Gynaecol Can. 2007;29(8):622–9 pmid:17714614
  48. 48. Martin A, Cox S, Jamieson D, Whiteman M, Kulkarni A, Tepper N. Respiratory Illness Hospitalizations Among Pregnant Women During Influenza Season, 1998–2008. Matern Child Health J. 2013;17(7):1325–31. pmid:23001819
  49. 49. Hartert TV, Neuzil KM, Shintani AK, Mitchel EF Jr, Snowden MS, Wood LB, et al. Maternal morbidity and perinatal outcomes among pregnant women with respiratory hospitalizations during influenza season. Am J Obstet Gynecol. 2003;189(6):1705–12. pmid:14710102
  50. 50. World Health Organization. WHO recommendations on the composition of influenza virus vaccines 2015 [Accessed 8 September 2015]. Available:
  51. 51. Sande CJ, Cane PA, Nokes DJ. The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants. Vaccine. 2014;32(37):4726–9. pmid:25005882
  52. 52. Reuman PD, Ayoub EM, Small PA. Effect of passive maternal antibody on influenza illness in children: a prospective study of influenza A in mother-infant pairs. Pediatr Infect Dis J. 1987;6(4):398–403. pmid:3588113
  53. 53. Puck J, Glezen W, Frank A, Six H. Protection of Infants from Infection with Influenza A virua by Transplacentally Acquired Antibody. J Infect Dis. 1980;142(6):844–9. pmid:7462695
  54. 54. Eick A, Karron R, Shaw J, Thumar B, Reid R, Santosham M, et al. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr Infect Dis J. 2008;27(3):207–12. pmid:18277934
  55. 55. Steinhoff MC, Omer SB, Roy E, Arifeen SE, Raqib R, Altaye M, et al. Influenza Immunization in Pregnancy—Antibody Responses in Mothers and Infants. N Engl J Med. 2010;362(17):1644–6. pmid:20427817
  56. 56. Englund JA, Mbawuike IN, Hammill H, Holleman MC, Baxter BD, Glezen WP. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J Infect Dis. 1993;168(3):647–56. pmid:8354906
  57. 57. Brandenburg AH, Groen J, Steensel-Moll HAv, Claas ECJ, Rothbarth PH, Neijens HJ, et al. Respiratory syncytial virus specific serum antibodies in infants under six months of age: Limited serological response upon infection. J Med Virol. 1997;52(1):97–104. pmid:9131465
  58. 58. Chu HY, Steinhoff MC, Magaret A, Zaman K, Roy E, Langdon G, et al. Respiratory Syncytial Virus Transplacental Antibody Transfer and Kinetics in Mother-Infant Pairs in Bangladesh. J Infect Dis. 2014;210(10):1582–9. pmid:24903663
  59. 59. Ochola R, Sande C, Fegan G, Scott PD, Medley GF, Cane PA, et al. The Level and Duration of RSV-Specific Maternal IgG in Infants in Kilifi Kenya. PLoS One. 2009;4(12):e8088. pmid:19956576
  60. 60. Model IMCI handbook: Integrated management of childhood illness: World Health Organisation; 2005. Available:
  61. 61. Iwane MK, Edwards KM, Szilagyi PG, Walker FJ, Griffin MR, Weinberg GA, et al. Population-Based Surveillance for Hospitalizations Associated With Respiratory Syncytial Virus, Influenza Virus, and Parainfluenza Viruses Among Young Children. Pediatrics. 2004;113(6):1758–64. pmid:15173503
  62. 62. Hasan R, Rhodes J, Thamthitiwat S, Olsen S, Prapasiri P, Naorat S, et al. Incidence and Etiology of Acute Lower Respiratory Tract Infections in Hospitalized Children Younger Than 5 Years in Rural Thailand. Pediatr Infect Dis J. 2014;33(2):E45–E52. pmid:24030346
  63. 63. Nair H, Simões EAF, Rudan I, Gessner BD, Azziz-Baumgartner E, Zhang JSF, et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. The Lancet. 2013;381(9875):1380–90.
  64. 64. Simoes EAF. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003;143(5, Supplement):118–26.
  65. 65. Jones M, Castile R, Davis S, Kisling J, Filbrun D, Flucke R, et al. Forced Expiratory Flows and Volumes in Infants. Am J Respir Crit Care Med. 2000;161(2):353–9. pmid:10673171
  66. 66. Hoo AF, Dezateux C, Hanrahan J, Cole T, Tepper R, Stocks J. Sex-Specific Prediction Equations for V˙maxFRC in Infancy. Am J Respir Crit Care Med. 2002;165(8):1084–92. pmid:11956049
  67. 67. Klein SL. The effects of hormones on sex differences in infection: from genes to behavior. Neurosci Biobehav Rev. 2000;24(6):627–38. pmid:10940438
  68. 68. Nolan T, Borja-Tabora C, Lopez P, Weckx L, Ulloa-Gutierrez R, Lazcano-Ponce E, et al. Prevalence and Incidence of Respiratory Syncytial Virus and Other Respiratory Viral Infections in Children Aged 6 Months to 10 Years With Influenza-like Illness Enrolled in a Randomized Trial. Clin Infect Dis. 2015;60(11):e80–e9. pmid:25673560
  69. 69. Chartrand C, Leeflang MMG, Minion J, Brewer T, Pai M. Accuracy of Rapid Influenza Diagnostic Tests: A Meta-analysis. Ann Intern Med. 2012;156(7):500–11. pmid:22371850
  70. 70. Falsey AR, Walsh EE. Respiratory Syncytial Virus Infection in Adults. Clin Microbiol Rev. 2000;13(3):371–84. pmid:10885982